vs
Prestige Consumer Healthcare Inc.（PBH）とROYAL GOLD INC（RGLD）の財務データ比較。上の社名をクリックして会社を切り替えられます
ROYAL GOLD INCの直近四半期売上が大きい（$375.3M vs $283.4M、Prestige Consumer Healthcare Inc.の約1.3倍）。ROYAL GOLD INCの純利益率が高く（24.9% vs 16.5%、差は8.5%）。ROYAL GOLD INCの前年同期比売上増加率が高い（85.3% vs -2.4%）。過去8四半期でROYAL GOLD INCの売上複合成長率が高い（58.8% vs 1.2%）
プレステージ・コンシューマー・ヘルスケア社はアメリカの企業で、一般用医薬品のヘルスケア製品および家庭用洗浄製品の販売・流通を手がけています。1996年にMedtech Products社、Prestige Brands International社、Spic and Span社の合併により設立され、本社はニューヨーク州タリータウン、バージニア州リンチバーグに製造工場を構えています。
ロイヤルゴールド社は貴金属のストリーミング権および鉱区使用権を専門とする大手企業で、稼働中・開発段階の鉱山プロジェクトに関する多様な権益ポートフォリオを取得・運用しています。対象は金、銀、銅で、事業は複数の大陸に展開し、直接採鉱のリスクを負わない事業モデルが特徴です。
PBH vs RGLD — 直接比較
損益計算書 — Q3 FY2026 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $283.4M | $375.3M |
| 純利益 | $46.7M | $93.6M |
| 粗利率 | 55.5% | 64.6% |
| 営業利益率 | 29.1% | 56.2% |
| 純利益率 | 16.5% | 24.9% |
| 売上前年比 | -2.4% | 85.3% |
| 純利益前年比 | -23.5% | -12.8% |
| EPS（希薄化後） | $0.97 | $1.04 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $283.4M | $375.3M | ||
| Q3 25 | $274.1M | $252.1M | ||
| Q2 25 | $249.5M | $209.6M | ||
| Q1 25 | $296.5M | $193.4M | ||
| Q4 24 | $290.3M | $202.6M | ||
| Q3 24 | $283.8M | $193.8M | ||
| Q2 24 | $267.1M | $174.1M | ||
| Q1 24 | $277.0M | $148.9M |
| Q4 25 | $46.7M | $93.6M | ||
| Q3 25 | $42.2M | $126.8M | ||
| Q2 25 | $47.5M | $132.3M | ||
| Q1 25 | $50.1M | $113.5M | ||
| Q4 24 | $61.0M | $107.4M | ||
| Q3 24 | $54.4M | $96.2M | ||
| Q2 24 | $49.1M | $81.2M | ||
| Q1 24 | $49.5M | $47.2M |
| Q4 25 | 55.5% | 64.6% | ||
| Q3 25 | 55.3% | 73.6% | ||
| Q2 25 | 56.2% | 72.6% | ||
| Q1 25 | 57.3% | 69.4% | ||
| Q4 24 | 55.5% | 70.3% | ||
| Q3 24 | 55.5% | 66.6% | ||
| Q2 24 | 54.7% | 64.7% | ||
| Q1 24 | 54.8% | 58.4% |
| Q4 25 | 29.1% | 56.2% | ||
| Q3 25 | 29.1% | 64.4% | ||
| Q2 25 | 28.8% | 67.7% | ||
| Q1 25 | 29.8% | 63.6% | ||
| Q4 24 | 31.7% | 65.9% | ||
| Q3 24 | 29.7% | 61.3% | ||
| Q2 24 | 27.0% | 58.6% | ||
| Q1 24 | 29.7% | 50.7% |
| Q4 25 | 16.5% | 24.9% | ||
| Q3 25 | 15.4% | 50.3% | ||
| Q2 25 | 19.0% | 63.1% | ||
| Q1 25 | 16.9% | 58.7% | ||
| Q4 24 | 21.0% | 53.0% | ||
| Q3 24 | 19.2% | 49.7% | ||
| Q2 24 | 18.4% | 46.6% | ||
| Q1 24 | 17.9% | 31.7% |
| Q4 25 | $0.97 | $1.04 | ||
| Q3 25 | $0.86 | $1.92 | ||
| Q2 25 | $0.95 | $2.01 | ||
| Q1 25 | $1.00 | $1.72 | ||
| Q4 24 | $1.22 | $1.63 | ||
| Q3 24 | $1.09 | $1.46 | ||
| Q2 24 | $0.98 | $1.23 | ||
| Q1 24 | $0.98 | $0.72 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $62.4M | $233.7M |
| 総負債低いほど良い | $1.0B | — |
| 株主資本純資産 | $1.8B | $7.2B |
| 総資産 | $3.5B | $9.5B |
| 負債/資本比率低いほどレバレッジが低い | 0.56× | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $62.4M | $233.7M | ||
| Q3 25 | $119.1M | $172.8M | ||
| Q2 25 | $139.5M | $248.2M | ||
| Q1 25 | $97.9M | $240.8M | ||
| Q4 24 | $50.9M | $195.5M | ||
| Q3 24 | $51.5M | $127.9M | ||
| Q2 24 | $34.3M | $74.2M | ||
| Q1 24 | $46.5M | $137.9M |
| Q4 25 | $1.0B | — | ||
| Q3 25 | $993.1M | — | ||
| Q2 25 | $992.7M | — | ||
| Q1 25 | $992.4M | — | ||
| Q4 24 | $992.0M | — | ||
| Q3 24 | $1.1B | $0 | ||
| Q2 24 | $1.1B | $50.0M | ||
| Q1 24 | $1.1B | — |
| Q4 25 | $1.8B | $7.2B | ||
| Q3 25 | $1.8B | $3.4B | ||
| Q2 25 | $1.9B | $3.3B | ||
| Q1 25 | $1.8B | $3.2B | ||
| Q4 24 | $1.8B | $3.1B | ||
| Q3 24 | $1.7B | $3.0B | ||
| Q2 24 | $1.7B | $3.0B | ||
| Q1 24 | $1.7B | $2.9B |
| Q4 25 | $3.5B | $9.5B | ||
| Q3 25 | $3.4B | $4.5B | ||
| Q2 25 | $3.4B | $3.6B | ||
| Q1 25 | $3.4B | $3.5B | ||
| Q4 24 | $3.3B | $3.4B | ||
| Q3 24 | $3.3B | $3.3B | ||
| Q2 24 | $3.3B | $3.3B | ||
| Q1 24 | $3.3B | $3.3B |
| Q4 25 | 0.56× | — | ||
| Q3 25 | 0.54× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.54× | — | ||
| Q4 24 | 0.55× | — | ||
| Q3 24 | 0.61× | 0.00× | ||
| Q2 24 | 0.65× | 0.02× | ||
| Q1 24 | 0.68× | — |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $78.3M | $241.7M |
| フリーキャッシュフロー営業CF - 設備投資 | $75.3M | — |
| FCFマージンFCF / 売上 | 26.6% | — |
| 設備投資強度設備投資 / 売上 | 1.1% | — |
| キャッシュ転換率営業CF / 純利益 | 1.68× | 2.58× |
| 直近12ヶ月FCF直近4四半期 | $267.2M | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $78.3M | $241.7M | ||
| Q3 25 | $57.5M | $174.0M | ||
| Q2 25 | $79.0M | $152.8M | ||
| Q1 25 | $61.8M | $136.4M | ||
| Q4 24 | $65.1M | $141.1M | ||
| Q3 24 | $69.8M | $136.7M | ||
| Q2 24 | $54.8M | $113.5M | ||
| Q1 24 | $66.9M | $138.3M |
| Q4 25 | $75.3M | — | ||
| Q3 25 | $55.4M | — | ||
| Q2 25 | $78.2M | — | ||
| Q1 25 | $58.4M | — | ||
| Q4 24 | $63.5M | — | ||
| Q3 24 | $67.8M | — | ||
| Q2 24 | $53.6M | — | ||
| Q1 24 | $63.8M | — |
| Q4 25 | 26.6% | — | ||
| Q3 25 | 20.2% | — | ||
| Q2 25 | 31.3% | — | ||
| Q1 25 | 19.7% | — | ||
| Q4 24 | 21.9% | — | ||
| Q3 24 | 23.9% | — | ||
| Q2 24 | 20.1% | — | ||
| Q1 24 | 23.0% | — |
| Q4 25 | 1.1% | — | ||
| Q3 25 | 0.8% | — | ||
| Q2 25 | 0.3% | — | ||
| Q1 25 | 1.2% | — | ||
| Q4 24 | 0.5% | — | ||
| Q3 24 | 0.7% | — | ||
| Q2 24 | 0.4% | — | ||
| Q1 24 | 1.1% | — |
| Q4 25 | 1.68× | 2.58× | ||
| Q3 25 | 1.36× | 1.37× | ||
| Q2 25 | 1.66× | 1.15× | ||
| Q1 25 | 1.23× | 1.20× | ||
| Q4 24 | 1.07× | 1.31× | ||
| Q3 24 | 1.28× | 1.42× | ||
| Q2 24 | 1.12× | 1.40× | ||
| Q1 24 | 1.35× | 2.93× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
PBH
| Womens Health | $51.8M | 18% |
| International OTC Healthcare | $47.7M | 17% |
| Gastrointestinal | $44.2M | 16% |
| Eye And Ear Care | $35.2M | 12% |
| Dermatologicals | $27.6M | 10% |
| Analgesics | $26.7M | 9% |
| Oral Care | $23.5M | 8% |
| Cough And Cold | $23.0M | 8% |
| Other Otc | $3.6M | 1% |
RGLD
| Gold | $216.9M | 58% |
| Pueblo Viejo | $47.3M | 13% |
| Andacollo | $32.6M | 9% |
| Silver | $32.1M | 9% |
| Other | $27.2M | 7% |
| Copper | $13.7M | 4% |
| Cortez Legacy Zone | $5.4M | 1% |
